Press release
Secondary Progressive Multiple Sclerosis Market to Set Phenomenal Growth From 2025 to 2034
Secondary Progressive Multiple Sclerosis Market
Secondary progressive multiple sclerosis (SPMS) is a chronic and often disabling phase of multiple sclerosis (MS), where patients transition from the relapsing-remitting stage to a steadily worsening neurological condition. SPMS leads to progressive disability, with symptoms such as muscle weakness, spasticity, mobility impairment, fatigue, and cognitive decline.
Historically, treatment options for SPMS were limited, focusing primarily on symptom management and supportive care. However, the past decade has brought disease-modifying therapies (DMTs) specifically approved for SPMS, including siponimod (Mayzent), cladribine, and ocrelizumab, significantly transforming the outlook for patients. Between 2024 and 2034, the SPMS market is expected to expand robustly, driven by therapeutic innovation, greater disease awareness, and government support for chronic neurological disorders.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/72072
Market Overview
• Market Size 2024: USD 5.6 billion (estimated)
• Forecasted Market Size 2034: USD 11.4 billion
• CAGR (2024-2034): 7.2%
Key Highlights
• Growing adoption of oral and infusion-based disease-modifying therapies.
• Increased investment in biologics, monoclonal antibodies, and gene therapies.
• Rising prevalence of MS, with ~2.8 million patients worldwide.
• Expansion of digital health monitoring and tele-neurology platforms.
Segmentation Analysis
By Product
• Disease-modifying therapies (DMTs):
o Siponimod (Mayzent)
o Ocrelizumab (Ocrevus)
o Cladribine (Mavenclad)
o Interferon-based therapies (supportive use)
o Pipeline biologics and gene therapies
• Symptomatic treatments (muscle relaxants, antidepressants, cognitive enhancers)
• Physical and occupational therapy services
• Assistive devices and mobility aids
By Platform
• Hospital pharmacies
• Retail pharmacies
• Specialty pharmacies
• Online pharmacies
By Technology
• Oral small molecules
• Infusion-based biologics (monoclonal antibodies)
• Gene therapy and regenerative medicine (pipeline)
• Digital disease-monitoring tools (apps, wearables)
By End Use
• Hospitals and neurology centers
• Specialty MS clinics
• Homecare and tele-neurology users
By Application
• Active SPMS (with relapses/inflammatory activity)
• Non-active SPMS (progressive without relapses)
• Advanced disability management
Summary:
The disease-modifying therapies segment dominates, with siponimod and ocrelizumab at the forefront. Future growth will come from gene therapies and next-generation biologics, alongside digital health innovations to improve long-term disease monitoring.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/72072/secondary-progressive-multiple-sclerosis-market
Regional Analysis
North America
• Largest market share in 2024, with the U.S. leading adoption of siponimod and ocrelizumab.
• Strong reimbursement frameworks and advanced MS research centers.
Europe
• High prevalence in Germany, UK, and Nordic countries.
• EU's strong support for MS clinical research driving innovation.
• Increasing adoption of biosimilars and generics for cost management.
Asia-Pacific
• Fastest-growing region (CAGR ~8.3%), fueled by rising MS prevalence in Japan, China, and India.
• Expanding healthcare infrastructure and tele-neurology adoption.
Middle East & Africa
• Smaller market size due to underdiagnosis and limited infrastructure.
• Growing collaborations improving access to DMTs.
Latin America
• Brazil and Mexico leading growth, with government-backed MS awareness initiatives.
• Increasing entry of generics improving affordability.
Summary:
North America and Europe dominate the market due to advanced healthcare systems, while Asia-Pacific emerges as the fastest-growing region, driven by increasing diagnosis and access to advanced therapies.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72072
Market Dynamics
Key Growth Drivers
• Rising prevalence of MS globally, with longer survival rates increasing SPMS cases.
• Strong uptake of disease-modifying therapies in SPMS treatment guidelines.
• Advances in biologics, gene therapies, and regenerative medicine.
• Growth of tele-neurology and digital disease monitoring tools.
Key Challenges
• High cost of DMTs limiting access in low- and middle-income countries.
• Side effects and safety concerns associated with long-term biologic use.
• Small but heterogeneous patient population complicating clinical trial design.
• Lack of curative treatments, with focus primarily on slowing progression.
Latest Trends
• Expansion of oral small molecules to improve convenience and adherence.
• Development of remyelination and neuroprotection therapies.
• Growing use of AI-powered digital biomarkers for early progression detection.
• Partnerships between pharma companies and MS advocacy groups to accelerate clinical research.
Competitor Analysis
Major Players
• Novartis AG (Mayzent - siponimod)
• Roche Holding AG (Ocrevus - ocrelizumab)
• Merck KGaA (Mavenclad - cladribine)
• Biogen Inc. (extensive MS portfolio including interferons, natalizumab)
• Sanofi S.A. (alemtuzumab, pipeline therapies)
• Bayer AG (interferon therapies, MS research)
• Teva Pharmaceutical Industries Ltd. (Copaxone legacy portfolio)
• Bristol Myers Squibb (zebinix and pipeline research)
• Atara Biotherapeutics, Inc. (cell-based therapies for progressive MS)
• TG Therapeutics, Inc. (ublituximab - new-generation monoclonal antibody)
Summary:
The SPMS market is dominated by Novartis, Roche, and Merck KGaA, while Biogen, Sanofi, and Bristol Myers Squibb continue to strengthen their pipelines. Innovative startups such as Atara are pushing into cell and gene therapies, aiming to transform the market.
Conclusion
The secondary progressive multiple sclerosis (SPMS) market is projected to nearly double, growing from USD 5.6 billion in 2024 to USD 11.4 billion by 2034, at a CAGR of 7.2%. Innovation in DMTs, gene therapies, and digital disease monitoring will drive sustained growth.
Key Takeaways:
• North America leads today, while Asia-Pacific will grow fastest over the next decade.
• Siponimod, ocrelizumab, and cladribine are redefining the SPMS therapeutic landscape.
• Gene therapy, remyelination, and neuroprotective approaches represent the next frontier.
• Digital health integration will enhance patient adherence, disease tracking, and real-world evidence collection.
This report is also available in the following languages : Japanese (二次進行性多発性硬化症市場), Korean (2차 진행성 다발성 경화증 시장), Chinese (继发性进行性多发性硬化症市场), French (Marché de la sclérose en plaques progressive secondaire), German (Markt für sekundär progrediente Multiple Sklerose), and Italian (Mercato della sclerosi multipla secondaria progressiva), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/72072
Our More Reports:
Vagus Nerve Stimulator (VNS) - Global Market
https://exactitudeconsultancy.com/reports/72120/vagus-nerve-stimulator-vns-global-market
Spinal Cord Injury (SCI) - Epidemiology forecast- 2034 Market
https://exactitudeconsultancy.com/reports/72122/spinal-cord-injury-sci-epidemiology-forecast-2034-market
Bronchopulmonary Dysplasia Patient Pool Analysis, Market
https://exactitudeconsultancy.com/reports/72124/bronchopulmonary-dysplasia-patient-pool-analysis-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Secondary Progressive Multiple Sclerosis Market to Set Phenomenal Growth From 2025 to 2034 here
News-ID: 4188431 • Views: …
More Releases from Exactitude Consultancy
Primary Progressive Aphasia Market New Product Development & Latest Trends
Introduction
Primary progressive aphasia (PPA) is a rare neurodegenerative disorder characterized by the gradual loss of language abilities, including speaking, understanding, reading, and writing. Unlike other forms of aphasia caused by stroke or trauma, PPA arises from progressive damage to the brain's language centers, often associated with frontotemporal lobar degeneration (FTLD) or Alzheimer's disease pathology.
As awareness of PPA grows and diagnostic imaging advances, more cases are being identified. However, treatment remains…
Partial Paralysis Market Growth, Applications, Innovations and Business Outlook …
Introduction
Partial paralysis, also known as paresis, is a condition characterized by the loss of voluntary muscle control in certain parts of the body due to neurological, muscular, or traumatic causes. Unlike complete paralysis, patients retain some degree of movement and sensation, though often with significant limitations. The condition is commonly linked to stroke, spinal cord injury, multiple sclerosis (MS), cerebral palsy, traumatic brain injury, and neuropathies.
Partial paralysis poses major challenges…
Opioid Overdose Market Massive Growth opportunity Ahead
Introduction
Opioid overdose is a critical public health emergency, particularly in North America, where misuse of prescription opioids, fentanyl has fueled a devastating epidemic. According to recent health data, over 100,000 opioid-related deaths occur annually worldwide, with the majority concentrated in the U.S. and Canada. Beyond mortality, opioid overdose contributes to massive healthcare costs, lost productivity, and significant social challenges.
The opioid overdose market centers on opioid antagonists, emergency response tools, and…
Schizophrenia Market Growth, Applications, Innovations and Business Outlook by 2 …
Introduction
Schizophrenia is a chronic and severe psychiatric disorder that affects how a person thinks, feels, and behaves. Characterized by symptoms such as hallucinations, delusions, disorganized speech, and impaired cognitive function, schizophrenia imposes a significant burden on patients, families, and healthcare systems. It affects about 24 million people worldwide, with most cases emerging in late adolescence or early adulthood.
Although there is no cure, treatment with antipsychotics, psychosocial support, and rehabilitation programs…
More Releases for SPMS
Secondary Progressive Multiple Sclerosis (SPMS) Market New Product Development & …
Introduction
Secondary Progressive Multiple Sclerosis (SPMS) is a form of multiple sclerosis (MS) that follows the relapsing-remitting stage and is characterized by a steady progression of neurological decline, often leading to increased disability. With limited treatment options historically available, patients faced significant unmet needs. However, advances in disease-modifying therapies (DMTs), improved diagnostic approaches, and growing investments in neurology research are shifting the treatment paradigm for SPMS.
According to Exactitude Consultancy, the global…
Secondary Progressive Multiple Sclerosis Clinical Trials | A Drug Pipeline Analy …
DelveInsight's 'Secondary Progressive Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Secondary Progressive Multiple Sclerosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Secondary Progressive Multiple Sclerosis pipeline domain.
Download a sample report @ https://www.delveinsight.com/report-store/secondary-progressive-multiple-sclerosis-spms-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Key Takeaways from the Secondary Progressive Multiple Sclerosis Pipeline Report
Over 5+ Secondary Progressive Multiple Sclerosis…
Secondary Progressive Multiple Sclerosis Clinical Trials | A Drug Pipeline Analy …
DelveInsight's 'Secondary Progressive Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Secondary Progressive Multiple Sclerosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Secondary Progressive Multiple Sclerosis pipeline domain.
Download a sample report @ https://www.delveinsight.com/report-store/secondary-progressive-multiple-sclerosis-spms-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Key Takeaways from the Secondary Progressive Multiple Sclerosis Pipeline Report
Over 5+ Secondary Progressive Multiple Sclerosis…
Detailed Analysis of Supplier-Procurement Management System (SPMS) Market | Busi …
Worldwide Market Reports has added a new research study on the Global "Supplier-Procurement Management System (SPMS) Market" 2024 by Size, Growth, Trends, and Dynamics, Forecast to 2031 which is a result of an extensive examination of the market patterns. This report covers a comprehensive investigation of the information that influences the market regarding fabricates, business providers, market players, and clients. The report provides data about the aspects which drive the…
Future Scope of Supplier-Procurement Management System (SPMS) Market 2023: Achie …
The business intelligence report on Supplier-Procurement Management System (SPMS) Market defines the major trends determining this domain's growth with respect to competitive and geographical landscape. Moreover, the study covers the challenges that impede industry development and offers insights into untapped opportunities that will spur business expansion during the forecast period 2023-2030.
Learn how to build a strategy to implement and a business case. Learn about Supplier-Procurement Management System (SPMS) market…
Pharmaceutical Growing Inclination of Secondary Progressive Multiple Sclerosis ( …
ResearchMoz presents Professional and In-depth Study of "Secondary Progressive Multiple Sclerosis (SPMS) Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025" with coming years Industries Trends, Projections of Global Growth, Major Key Player and Case Study, Review, Share, Size, Effect.
' '
Multiple sclerosis (MS), which is also known as disseminated sclerosis, is an inflammatory disease of the nervous system. It is primarily characterized by the…
